Medical Cannabis During Chemoradiation for Head and Neck Cancer

Inclusion Criteria:

- Patients must have histologically confirmed squamous cell carcinoma of the head and
neck region planned for definitive or adjuvant treatment with concurrent radiation
therapy and systemic therapy

- Patients may receive platinum-based chemotherapy or cetuximab concurrently with
radiation therapy

- Age >18 years and ECOG performance status <2 (Karnofsky >60).

- Patients must be willing to use medically certified cannabis as directed after study
enrollment

- Patients must be able to read English, Spanish, or French fluently

- Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

- Prior diagnosis of cannabis use disorder as defined in the DSM-V

- Current opioid use disorder on maintenance opioid therapy

- Current active use of smoked cannabis or cannabis derivatives AND unwillingness to
cease use of non-medically certified cannabis for the duration of study participation.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to cannabis derivatives

- Uncontrolled intercurrent illness including, but not limited to, symptomatic
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit compliance with study requirements.